drugset / Trial / NCT06283303
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
Timeline
- Start
- 2024-04-02
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | T3011 | Other / unclassified | 3e+08 unknown | Other |
| Subject | T3011 | Other / unclassified | 1e+09 unknown | Other |
| Subject | Toripalimab | Monoclonal antibody | 80 mg | Intravenous |